Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265249 | 1.00 | ABCC9 (0.54) | ABCC9ABCB1 | |
| SCHEMBL13080434 | 0.85 | ABCC9 (0.67) | ABCC9ABCB1 | |
| SCHEMBL482161 | 0.85 | ABCC9 (0.67) | ABCC9ABCB1 | |
| SCHEMBL13079601 | 0.85 | ABCC9 (0.53) | ABCC9ABCB1 | |
| SCHEMBL482215 | 0.85 | ABCC9 (0.53) | ABCC9ABCB1 | |
| SCHEMBL13050118 | 0.85 | MAPT (0.39) | ABCC9 | |
| SCHEMBL10266127 | 0.82 | ABCC9 (0.53) | ABCC9ABCB1 | |
| SCHEMBL481999 | 0.82 | ABCC9 (0.53) | ABCC9ABCB1 | |
| SCHEMBL8612166 | 0.73 | ABCC9 (0.57) | ABCC9ABCB1 | |
| SCHEMBL8612163 | 0.73 | ABCC9 (0.57) | ABCC9ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1940516-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027780-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885ABCB1 158/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885ABCB1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.